1.
Journal of Leukemia & Lymphoma
;
(12): 695-697, 2021.
Article
Dans Chinois
| WPRIM
| ID: wpr-907235
Résumé
Hemophagocytic syndrome (HPS) is a rare, life-threatening inflammatory response syndrome characterized by overactivation of the immune system, which leads to organ damage. Secondary HPS is usually triggered by infection, tumor and autoimmune disease. It has been clinically found that many HPS-like manifestations also occur during drug therapy. This article reviews the related progress of HPS induced by immune checkpoint inhibitors, ibrutinib and lamotrigine, in order to provide a guidance for clinical practice.